Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized phase 2 study of subcutaneous ACT-246475 in adults with acute myocardial infarction
MOH_2018-08-21_003603Phase 2Not yet recruiting
- Sponsor
- Idorsia
- Start
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of selatogrel in myocardial infarction (MI) (2 arms), sponsored by Idorsia. Primary endpoint: Inhibition of platelet aggregation at 30 minutes. Planned start Jul 2018; status: not yet recruiting.
02
Drugs
selatogrel
03
Conditions
myocardial infarction (MI)
Beyond the preview
Go deeper on MOH_2018-08-21_003603.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2018-08-21_003603.